However, there is now immense potential for disruption in TB Care:

• There is now a sense of optimism in TB that science is paying off.
• Several new tools are available (new vaccine candidate, shorter regimens, new diagnostics), but they have not come together to serve TB patients.
• Stakeholders, especially innovators, are beginning to see how various innovations fit into the larger ecosystem, but they need to be engaged and synergized.
• While there are PDPs focused on diagnostics, drugs, and vaccines, there are also various emerging technological solutions that do not neatly fall into these traditional product categories, such as: